Washington Report Articles
The introduction of legislation to ensure access by patients to high-cost therapies continues to increase throughout the country.
The U.S. Department of Health and Human Services has announced it will provide $750 million to fund new prevention and public health programs, made available through the new healthcare law’s Prevention and Public Health Fund.
As of April 2011, many cuts to healthcare spending are being proposed and expected.
The House Judiciary Committee is working to pass medical tort reform legislation.
In August 2010, the Centers for Medicare and Medicaid Services proposed to change the reimbursement rate of separately payable, non-pass-through drugs and biologicals.
In Massachusetts, a panel of state officials and healthcare executives moved toward global payments by drafting a first-in-the-nation blueprint for scrapping current fee-forservice payments.
Specialty medications costing more than $600 per year are now classified under two new tiers of Medicare Part D drug benefit plan.
Many questions remain unanswered about the healthcare reform recently enacted into law, but here's what we do know.
The U.S. Food and Drug Administration and the European Medicines Agency has launched a bilateral Good Clinical Practices Initiative, designed to ensure that clinical trials submitted in drug marketing applications in the United States and Europe are conducted uniformly, appropriately and ethically.
In addition to the new health insurance reform law, states are looking into some of the most important issues that affect patients’ access to care.
On March 23, 2010, President Barack Obama signed into law the new healthcare reform legislation titled the Affordable Health Care for America Act.